Black Diamond Therapeutics Inc (NASDAQ: BDTX) is 41.81% higher on its value in year-to-date trading and has touched a low of $1.62 and a high of $7.66 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BDTX stock was last observed hovering at around $4.17 in the last trading session, with the day’s loss setting it -0.19%.
Currently trading at $3.98, the stock is -21.43% and -27.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.96 million and changing -4.44% at the moment leaves the stock -17.63% off its SMA200. BDTX registered 43.35% gain for a year compared to 6-month gain of -20.30%. The firm has a 50-day simple moving average (SMA 50) of $5.4233 and a 200-day simple moving average (SMA200) of $4.844175.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -30.94% loss in the last 1 month and extending the period to 3 months gives it a -10.25%, and is -5.12% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.02% over the week and 9.65% over the month.
Black Diamond Therapeutics Inc (BDTX) has around 54 employees, a market worth around $225.15M and $0.00M in sales. Distance from 52-week low is 145.99% and -47.98% from its 52-week high. The company has generated returns on investments over the last 12 months (-61.23%).
The EPS is expected to grow by 26.34% this year
122.0 institutions hold shares in Black Diamond Therapeutics Inc (BDTX), with institutional investors hold 97.44% of the company’s shares. The shares outstanding are 51.65M, and float is at 43.06M with Short Float at 13.61%. Institutions hold 95.23% of the Float.
The top institutional shareholder in the company is T. ROWE PRICE INVESTMENT MANAGEMENT, INC. with over 10.66 million shares valued at $49.67 million. The investor’s holdings represent 20.5751 of the BDTX Shares outstanding. As of 2024-06-30, the second largest holder is BELLEVUE GROUP AG with 8.52 million shares valued at $39.69 million to account for 16.4409 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 4.45 million shares representing 8.5869 and valued at over $20.73 million, while BLACKROCK INC. holds 6.2096 of the shares totaling 3.22 million with a market value of $14.99 million.
Black Diamond Therapeutics Inc (BDTX) Insider Activity
The most recent transaction is an insider sale by Versant Venture Capital VI, L., the company’s 10% Owner. SEC filings show that Versant Venture Capital VI, L. sold 221,600 shares of the company’s common stock on Aug 28 ’24 at a price of $6.32 per share for a total of $1.4 million. Following the sale, the insider now owns 3.73 million shares.
Still, SEC filings show that on Jul 26 ’24, David Epstein (Former Employee) Proposed Sale 50,000 shares at an average price of $6.20 for $0.31 million. The insider now directly holds shares of Black Diamond Therapeutics Inc (BDTX).
